Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.
This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.
Extensive Worldwide Technical and Market Analyses Presented in this Report: